boxplot analysis Search Results


90
SPSS Inc boxplot analysis
Boxplot Analysis, supplied by SPSS Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/boxplot analysis/product/SPSS Inc
Average 90 stars, based on 1 article reviews
boxplot analysis - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier

90
Epigenomics ag boxplot analysis
Boxplot Analysis, supplied by Epigenomics ag, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/boxplot analysis/product/Epigenomics ag
Average 90 stars, based on 1 article reviews
boxplot analysis - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier

90
GraphPad Software Inc boxplot comparisons of gene expression and statistical analysis
Boxplot Comparisons Of Gene Expression And Statistical Analysis, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/boxplot comparisons of gene expression and statistical analysis/product/GraphPad Software Inc
Average 90 stars, based on 1 article reviews
boxplot comparisons of gene expression and statistical analysis - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier

90
GraphPad Software Inc boxplots and heatmap for aqua peptides analysis
Targeted proteomics by automated quantification proteomics approach further characterised ATA+(a) and ATA+(b) group (validation cohort). ( A ) Heatmap represents selected proteins expression among groups. ( B ) <t>Boxplots</t> represent detailed overexpressed proteins in ATA+(a) group both vs ATA+(b) and HC ( B ). NS: non-significant (p value>0.05); *p value<0.05; **p value<0.01; ***p value<0.001; ***p value<0.0001. ATA+, anti-topoisomerase-I positive patients (N=24); ATA+(a), ATA+group a (N=11); ATA+(b), ATA+group b (N=13); ACA+, anti-centromere positive patients (N=18); ARA+, anti-RNA polymerase-III positive patients (N=5); ATA+, anti-topoisomerase-I positive patients; ATA+ (a) , anti-topoisomerase-I positive patients group a; ATA+ (b) , anti-topoisomerase-I positive patients group b; CDH2, cadherin 2; CDH5, VE-cadherin; CISD1, CDGSH iron sulphur domain 1; EIF2B3, eukaryotic translation initiation factor 2B subunit gamma; EPS15, epidermal growth factor receptor pathway substrate 15; FKBP11, FKBP prolyl isomerase 11; HC, healthy controls (N=20); ICAM-1, intercellular adhesion molecule 1; ITGA3, integrin alpha-3; NRBP1, nuclear receptor-binding protein; P4HA2, prolyl 4-hydroxylase subunit alpha-2; PNN, desmosome associated protein; RAE1, Rae1 RNA export 1; SEL1L, adaptor subunit of SYVN1 ubiquitin ligase; SNRPA, small nuclear ribonucleoprotein polypeptide A; STAM, signal transducing adaptor molecule; STK24, serine/threonine-protein kinase 24; TPP1, tripeptidyl-peptidase 1; TTN, titin.
Boxplots And Heatmap For Aqua Peptides Analysis, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/boxplots and heatmap for aqua peptides analysis/product/GraphPad Software Inc
Average 90 stars, based on 1 article reviews
boxplots and heatmap for aqua peptides analysis - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier

90
SAS institute boxplots, frequency distributions, and principal component analysis (pca) analyses
Targeted proteomics by automated quantification proteomics approach further characterised ATA+(a) and ATA+(b) group (validation cohort). ( A ) Heatmap represents selected proteins expression among groups. ( B ) <t>Boxplots</t> represent detailed overexpressed proteins in ATA+(a) group both vs ATA+(b) and HC ( B ). NS: non-significant (p value>0.05); *p value<0.05; **p value<0.01; ***p value<0.001; ***p value<0.0001. ATA+, anti-topoisomerase-I positive patients (N=24); ATA+(a), ATA+group a (N=11); ATA+(b), ATA+group b (N=13); ACA+, anti-centromere positive patients (N=18); ARA+, anti-RNA polymerase-III positive patients (N=5); ATA+, anti-topoisomerase-I positive patients; ATA+ (a) , anti-topoisomerase-I positive patients group a; ATA+ (b) , anti-topoisomerase-I positive patients group b; CDH2, cadherin 2; CDH5, VE-cadherin; CISD1, CDGSH iron sulphur domain 1; EIF2B3, eukaryotic translation initiation factor 2B subunit gamma; EPS15, epidermal growth factor receptor pathway substrate 15; FKBP11, FKBP prolyl isomerase 11; HC, healthy controls (N=20); ICAM-1, intercellular adhesion molecule 1; ITGA3, integrin alpha-3; NRBP1, nuclear receptor-binding protein; P4HA2, prolyl 4-hydroxylase subunit alpha-2; PNN, desmosome associated protein; RAE1, Rae1 RNA export 1; SEL1L, adaptor subunit of SYVN1 ubiquitin ligase; SNRPA, small nuclear ribonucleoprotein polypeptide A; STAM, signal transducing adaptor molecule; STK24, serine/threonine-protein kinase 24; TPP1, tripeptidyl-peptidase 1; TTN, titin.
Boxplots, Frequency Distributions, And Principal Component Analysis (Pca) Analyses, supplied by SAS institute, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/boxplots, frequency distributions, and principal component analysis (pca) analyses/product/SAS institute
Average 90 stars, based on 1 article reviews
boxplots, frequency distributions, and principal component analysis (pca) analyses - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier

90
GraphPad Software Inc boxplot analysis
Performance of HILAQ. (a) The number of NSP identified by HILAQ protocol was significantly increased over QuaNCAT. In the bottom table, confident NSP means the NSP overlapped in all three biological replicates. NSP sensitivity is the ratio of modified peptide/protein identifications over baseline. (**p<0.001; one tailed unpaired t-test, comparison with QuaNCAT) (b) Composition of identified protein by HILAQ and QuaNCAT. (c) Venn diagram analysis on quantification by HILAQ or QuaNCAT. Only proteins quantified confidently by all three replicates of HILAQ or QuaNCAT were counted and compared for this analysis. (d) Normal distribution of replicates of HILAQ and QuaNCAT. All datasets were not normalized. (e) <t>Boxplot</t> analysis on every replicate of HILAQ and QuaNCAT using Graphpad Prism (version 5.01). The boxplot was created with Turkey whiskers. (f) Proteins quantified by all three replicate of HILAQ or QuaNCAT were annotated using web based tool PANTHER (http://pantherdb.org/). There are twiceas many pathways enriched in HILAQ than QuaNCAT. (g) The quantification of NSP between HT22 and HEK293Tcell lines. The peptides ratios from two independent HILAQ experiments were compared. The AHA and HAHA labels were swapped in the two experiments.
Boxplot Analysis, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/boxplot analysis/product/GraphPad Software Inc
Average 90 stars, based on 1 article reviews
boxplot analysis - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier

90
OriginLab corp visualization of boxplots in alpha diversity, number and abundance and the principal coordinate analysis (pcoa) plots
Performance of HILAQ. (a) The number of NSP identified by HILAQ protocol was significantly increased over QuaNCAT. In the bottom table, confident NSP means the NSP overlapped in all three biological replicates. NSP sensitivity is the ratio of modified peptide/protein identifications over baseline. (**p<0.001; one tailed unpaired t-test, comparison with QuaNCAT) (b) Composition of identified protein by HILAQ and QuaNCAT. (c) Venn diagram analysis on quantification by HILAQ or QuaNCAT. Only proteins quantified confidently by all three replicates of HILAQ or QuaNCAT were counted and compared for this analysis. (d) Normal distribution of replicates of HILAQ and QuaNCAT. All datasets were not normalized. (e) <t>Boxplot</t> analysis on every replicate of HILAQ and QuaNCAT using Graphpad Prism (version 5.01). The boxplot was created with Turkey whiskers. (f) Proteins quantified by all three replicate of HILAQ or QuaNCAT were annotated using web based tool PANTHER (http://pantherdb.org/). There are twiceas many pathways enriched in HILAQ than QuaNCAT. (g) The quantification of NSP between HT22 and HEK293Tcell lines. The peptides ratios from two independent HILAQ experiments were compared. The AHA and HAHA labels were swapped in the two experiments.
Visualization Of Boxplots In Alpha Diversity, Number And Abundance And The Principal Coordinate Analysis (Pcoa) Plots, supplied by OriginLab corp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/visualization of boxplots in alpha diversity, number and abundance and the principal coordinate analysis (pcoa) plots/product/OriginLab corp
Average 90 stars, based on 1 article reviews
visualization of boxplots in alpha diversity, number and abundance and the principal coordinate analysis (pcoa) plots - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier

Image Search Results


Targeted proteomics by automated quantification proteomics approach further characterised ATA+(a) and ATA+(b) group (validation cohort). ( A ) Heatmap represents selected proteins expression among groups. ( B ) Boxplots represent detailed overexpressed proteins in ATA+(a) group both vs ATA+(b) and HC ( B ). NS: non-significant (p value>0.05); *p value<0.05; **p value<0.01; ***p value<0.001; ***p value<0.0001. ATA+, anti-topoisomerase-I positive patients (N=24); ATA+(a), ATA+group a (N=11); ATA+(b), ATA+group b (N=13); ACA+, anti-centromere positive patients (N=18); ARA+, anti-RNA polymerase-III positive patients (N=5); ATA+, anti-topoisomerase-I positive patients; ATA+ (a) , anti-topoisomerase-I positive patients group a; ATA+ (b) , anti-topoisomerase-I positive patients group b; CDH2, cadherin 2; CDH5, VE-cadherin; CISD1, CDGSH iron sulphur domain 1; EIF2B3, eukaryotic translation initiation factor 2B subunit gamma; EPS15, epidermal growth factor receptor pathway substrate 15; FKBP11, FKBP prolyl isomerase 11; HC, healthy controls (N=20); ICAM-1, intercellular adhesion molecule 1; ITGA3, integrin alpha-3; NRBP1, nuclear receptor-binding protein; P4HA2, prolyl 4-hydroxylase subunit alpha-2; PNN, desmosome associated protein; RAE1, Rae1 RNA export 1; SEL1L, adaptor subunit of SYVN1 ubiquitin ligase; SNRPA, small nuclear ribonucleoprotein polypeptide A; STAM, signal transducing adaptor molecule; STK24, serine/threonine-protein kinase 24; TPP1, tripeptidyl-peptidase 1; TTN, titin.

Journal: RMD Open

Article Title: Immunoglobulins G from Patients with Systemic Sclerosis Modify the Molecular Signatures of Endothelial Cells

doi: 10.1136/rmdopen-2024-004290

Figure Lengend Snippet: Targeted proteomics by automated quantification proteomics approach further characterised ATA+(a) and ATA+(b) group (validation cohort). ( A ) Heatmap represents selected proteins expression among groups. ( B ) Boxplots represent detailed overexpressed proteins in ATA+(a) group both vs ATA+(b) and HC ( B ). NS: non-significant (p value>0.05); *p value<0.05; **p value<0.01; ***p value<0.001; ***p value<0.0001. ATA+, anti-topoisomerase-I positive patients (N=24); ATA+(a), ATA+group a (N=11); ATA+(b), ATA+group b (N=13); ACA+, anti-centromere positive patients (N=18); ARA+, anti-RNA polymerase-III positive patients (N=5); ATA+, anti-topoisomerase-I positive patients; ATA+ (a) , anti-topoisomerase-I positive patients group a; ATA+ (b) , anti-topoisomerase-I positive patients group b; CDH2, cadherin 2; CDH5, VE-cadherin; CISD1, CDGSH iron sulphur domain 1; EIF2B3, eukaryotic translation initiation factor 2B subunit gamma; EPS15, epidermal growth factor receptor pathway substrate 15; FKBP11, FKBP prolyl isomerase 11; HC, healthy controls (N=20); ICAM-1, intercellular adhesion molecule 1; ITGA3, integrin alpha-3; NRBP1, nuclear receptor-binding protein; P4HA2, prolyl 4-hydroxylase subunit alpha-2; PNN, desmosome associated protein; RAE1, Rae1 RNA export 1; SEL1L, adaptor subunit of SYVN1 ubiquitin ligase; SNRPA, small nuclear ribonucleoprotein polypeptide A; STAM, signal transducing adaptor molecule; STK24, serine/threonine-protein kinase 24; TPP1, tripeptidyl-peptidase 1; TTN, titin.

Article Snippet: Boxplots and heatmap for AQUA peptides analysis were performed with GraphPad Prism (V.10.1.0, San Diego, California, USA).

Techniques: Targeted Proteomics, Biomarker Discovery, Expressing, Binding Assay, Ubiquitin Proteomics

Performance of HILAQ. (a) The number of NSP identified by HILAQ protocol was significantly increased over QuaNCAT. In the bottom table, confident NSP means the NSP overlapped in all three biological replicates. NSP sensitivity is the ratio of modified peptide/protein identifications over baseline. (**p<0.001; one tailed unpaired t-test, comparison with QuaNCAT) (b) Composition of identified protein by HILAQ and QuaNCAT. (c) Venn diagram analysis on quantification by HILAQ or QuaNCAT. Only proteins quantified confidently by all three replicates of HILAQ or QuaNCAT were counted and compared for this analysis. (d) Normal distribution of replicates of HILAQ and QuaNCAT. All datasets were not normalized. (e) Boxplot analysis on every replicate of HILAQ and QuaNCAT using Graphpad Prism (version 5.01). The boxplot was created with Turkey whiskers. (f) Proteins quantified by all three replicate of HILAQ or QuaNCAT were annotated using web based tool PANTHER (http://pantherdb.org/). There are twiceas many pathways enriched in HILAQ than QuaNCAT. (g) The quantification of NSP between HT22 and HEK293Tcell lines. The peptides ratios from two independent HILAQ experiments were compared. The AHA and HAHA labels were swapped in the two experiments.

Journal: Journal of proteome research

Article Title: HILAQ: A Novel Strategy for Newly Synthesized Protein Quantification

doi: 10.1021/acs.jproteome.7b00005

Figure Lengend Snippet: Performance of HILAQ. (a) The number of NSP identified by HILAQ protocol was significantly increased over QuaNCAT. In the bottom table, confident NSP means the NSP overlapped in all three biological replicates. NSP sensitivity is the ratio of modified peptide/protein identifications over baseline. (**p<0.001; one tailed unpaired t-test, comparison with QuaNCAT) (b) Composition of identified protein by HILAQ and QuaNCAT. (c) Venn diagram analysis on quantification by HILAQ or QuaNCAT. Only proteins quantified confidently by all three replicates of HILAQ or QuaNCAT were counted and compared for this analysis. (d) Normal distribution of replicates of HILAQ and QuaNCAT. All datasets were not normalized. (e) Boxplot analysis on every replicate of HILAQ and QuaNCAT using Graphpad Prism (version 5.01). The boxplot was created with Turkey whiskers. (f) Proteins quantified by all three replicate of HILAQ or QuaNCAT were annotated using web based tool PANTHER (http://pantherdb.org/). There are twiceas many pathways enriched in HILAQ than QuaNCAT. (g) The quantification of NSP between HT22 and HEK293Tcell lines. The peptides ratios from two independent HILAQ experiments were compared. The AHA and HAHA labels were swapped in the two experiments.

Article Snippet: All datasets were not normalized. ( e ) Boxplot analysis on every replicate of HILAQ and QuaNCAT using Graphpad Prism (version 5.01).

Techniques: Modification, One-tailed Test, Comparison